{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:44:21Z","timestamp":1782787461845,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"DOI":"10.1007\/s00213-026-07120-w","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:07:53Z","timestamp":1782785273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["OPRD1 rs4654327 and Outcomes of Extended-Release Naltrexone in Alcohol Use Disorder: An Exploratory Prospective Pharmacogenetic Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4942-8556","authenticated-orcid":false,"given":"Valentin","family":"Skryabin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Miroshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Masyakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Pozdniakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ivanchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Shipitsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"4","key":"7120_CR1","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3350\/cmh.2020.0160","volume":"26","author":"SH Park","year":"2020","unstructured":"Park SH, Kim DJ (2020) Global and regional impacts of alcohol use on public health: Emphasis on alcohol policies. Clin Mol Hepatol 26(4):652\u2013661. https:\/\/doi.org\/10.3350\/cmh.2020.0160","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"7120_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/wps.21073","volume":"22","author":"ND Volkow","year":"2023","unstructured":"Volkow ND, Blanco C (2023) Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry 22(2):203\u2013229. https:\/\/doi.org\/10.1002\/wps.21073","journal-title":"World Psychiatry"},{"issue":"3","key":"7120_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/npr2.12028","volume":"38","author":"WW Shen","year":"2018","unstructured":"Shen WW (2018) Anticraving therapy for alcohol use disorder: A clinical review. Neuropsychopharmacol Rep 38(3):105\u2013116","journal-title":"Neuropsychopharmacol Rep"},{"issue":"10","key":"7120_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40263-013-0096-4","volume":"27","author":"MJ Niciu","year":"2013","unstructured":"Niciu MJ, Arias AJ (2013) Targeted opioid receptor antagonists in the treatment of alcohol use disorders. CNS Drugs 27(10):777\u2013787","journal-title":"CNS Drugs"},{"issue":"13","key":"7120_CR5","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","volume":"293","author":"JC Garbutt","year":"2005","unstructured":"Garbutt JC, Kranzler HR, O\u2019Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW, Vivitrex Study Group (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293(13):1617\u20131625. https:\/\/doi.org\/10.1001\/jama.293.13.1617","journal-title":"JAMA"},{"issue":"10","key":"7120_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.tips.2011.06.008","volume":"32","author":"AA Pradhan","year":"2011","unstructured":"Pradhan AA, Befort K, Nozaki C, Gav\u00e9riaux-Ruff C, Kieffer BL (2011) The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 32(10):581\u2013590. https:\/\/doi.org\/10.1016\/j.tips.2011.06.008","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"7120_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","volume":"36","author":"PE Lutz","year":"2013","unstructured":"Lutz PE, Kieffer BL (2013) Opioid receptors: distinct roles in mood disorders. Trends Neurosci 36(3):195\u2013206. https:\/\/doi.org\/10.1016\/j.tins.2012.11.002","journal-title":"Trends Neurosci"},{"key":"7120_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/164_2016_30","volume":"247","author":"D Alongkronrusmee","year":"2018","unstructured":"Alongkronrusmee D, Chiang T, van Rijn RM (2018) Delta Opioid Pharmacology in Relation to Alcohol Behaviors. Handb Exp Pharmacol 247:199\u2013225. https:\/\/doi.org\/10.1007\/164_2016_30","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"7120_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pbb.2012.08.019","volume":"103","author":"JR Ashenhurst","year":"2012","unstructured":"Ashenhurst JR, Bujarski S, Ray LA (2012) Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharmacol Biochem Behav 103(2):253\u2013259. https:\/\/doi.org\/10.1016\/j.pbb.2012.08.019","journal-title":"Pharmacol Biochem Behav"},{"issue":"10","key":"7120_CR10","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/npp.2013.99","volume":"38","author":"RC Crist","year":"2013","unstructured":"Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, Ling W, Hillhouse MP, Bruce RD, Woody G, Berrettini WH (2013) An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology 38(10):2003\u20132010. https:\/\/doi.org\/10.1038\/npp.2013.99","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"7120_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1089\/omi.2017.0057","volume":"21","author":"X Gao","year":"2017","unstructured":"Gao X, Wang Y, Lang M, Yuan L, Reece AS, Wang W (2017) Contribution of Genetic Polymorphisms and Haplotypes in DRD2, BDNF, and Opioid Receptors to Heroin Dependence and Endophenotypes Among the Han Chinese. OMICS 21(7):404\u2013412. https:\/\/doi.org\/10.1089\/omi.2017.0057","journal-title":"OMICS"},{"issue":"1","key":"7120_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41398-021-01439-y","volume":"11","author":"O Levran","year":"2021","unstructured":"Levran O, Randesi M, Adelson M, Kreek MJ (2021) OPRD1 SNPs associated with opioid addiction are cis-eQTLs for the phosphatase and actin regulator 4 gene, PHACTR4, a mediator of cytoskeletal dynamics. Transl Psychiatry 11(1):316. https:\/\/doi.org\/10.1038\/s41398-021-01439-y","journal-title":"Transl Psychiatry"},{"issue":"8","key":"7120_CR13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","volume":"23","author":"BA Flannery","year":"1999","unstructured":"Flannery BA, Volpicelli JR, Pettinati HM (1999) Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 23(8):1289\u20131295","journal-title":"Alcohol Clin Exp Res"},{"key":"7120_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta PsychiatrScand Suppl 334:1\u2013100. https:\/\/doi.org\/10.1111\/j.1600-0447.1987.tb10566.x","journal-title":"Acta PsychiatrScand Suppl"},{"key":"7120_CR15","unstructured":"Altshuler VB (1994) Craving to alcohol: clinical and therapeutic issues. Moscow; Image,, p 216"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07120-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-026-07120-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07120-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:08:01Z","timestamp":1782785281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-026-07120-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":15,"alternative-id":["7120"],"URL":"https:\/\/doi.org\/10.1007\/s00213-026-07120-w","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the procedures conducted in our study followed the principles set forth in the Declaration of Helsinki. Local Ethics Committee of the Russian Medical Academy of Continuous Professional Education approved this study (Protocol number 11 of November 28, 2016). Study participants were provided with consent forms prior to the commencement of the research. A registered practitioner counselled the patients, in the patients\u2019 native language where needed, providing detailed explanations of the research, and addressing all patient inquiries.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}